drugset / Trial / NCT05899985
Magnetic Sentinel Lymph Node Mapping in Upper Gastro-Intestinal Cancer: A Feasibility Clinical Investigation
Active not recruiting
60 enrolled
Ferronova Pty Ltd
Austin Health · collabFlinders Medical Centre · collabPeter MacCallum Cancer Centre, Australia · collabRoyal Adelaide Hospital · collabSouth Australian Health and Medical Research Institute · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a multi-centre, partially blinded, side-by-side comparator study to assess the safety and tolerability, feasibility, and potential added diagnostic and clinical value of using the FerroTrace® and FerroMag Sentinel Lymph Node Mapping (SLNM) System for mapping sentinel lymph nodes (SLNs) in subjects with gastric, gastric-oesophageal junction, and oesophageal cancers, consisting of a safety lead-in phase and an expansion phase.
Timeline
- Start
- 2024-03-21
- Primary completion
- 2026-05-30
- Completion
- 2029-05-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | FerroTrace | Diagnostic / imaging agent | — | Other |